Adm1n at 00:27, 15 February 2015

2015-02-15T00:27:57Z

Adm1n: Created page with "AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. AM-679 was one of the first..."

2015-02-15T00:27:19Z

Created page with "AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. AM-679 was one of the first..."

New page

[[AM-679]] is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at [[CB1]] and 49.5nM at [[CB2]]. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised [[cannabinoid]] ligands that are now widely used in research, including the potent CB1 agonists [[AM-694]] and [[AM-2233]], and the selective CB2 agonist [[AM-1241]]. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.

==See also==

* [[RCS-4]]
* [[AM-694]]
* [[AM-2233]]

← Older revision		Revision as of 00:27, 15 February 2015
Line 1:		Line 1:
−	[[AM-679]] is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at [[CB1]] and 49.5nM at [[CB2]]. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised [[cannabinoid]] ligands that are now widely used in research, including the potent CB1 agonists [[AM-694]] and [[AM-2233]], and the selective CB2 agonist [[AM-1241]]. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.	+	'''AM-679''' is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at [[CB1]] and 49.5nM at [[CB2]]. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised [[cannabinoid]] ligands that are now widely used in research, including the potent CB1 agonists [[AM-694]] and [[AM-2233]], and the selective CB2 agonist [[AM-1241]]. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.

AM-679 (cannabinoid) - Revision history

Adm1n at 00:27, 15 February 2015

Adm1n: Created page with "AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. AM-679 was one of the first..."